US FDA approves Urogen's bladder cancer drug
12/06/2025 17:44
June 12 (Reuters) - The U.S. Food and Drug Administration has approved Urogen Pharma's UR8.F drug to treat a type of bladder cancer, the regulator said on Thursday. (Reporting by Padmanabhan Ananthan and Kamal Choudhury in Bengaluru; Editing by Leroy Leo) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors